Achievement

    Original Research Articles 

(Sorted present to past)

44. Hayabuchi H, Tokifuji Y, Takahashi H, Amagai M, Yoshimura A, Chikuma S (Corresponding Author.) Disruption of post-thymic tolerance in skin-reactive TCR transgenic mice through the interaction of lymphopenia and intestinal microbiota. Int Immunol. Apr 5: dxae018, 2024

43. Tokifuji Y, Hayabuchi H, Sasaki T, Hara-Chikuma M, Hirota K, Takahashi H, Amagai M, Yoshimura A, Chikuma S (Corresponding Author.) Targeting abatacept-resistant T-helper-17 cells by aldehyde dehydrogenase inhibition. iScience 27: 108646, 2023

42. Nakamichi R*, Hishikawa A*, Chikuma S, Yoshimura A, Sasaki T, Hashiguchi A, Abe T, Tokuhara T, Yoshimoto N, Nishimura ES, Hama EY, Azegami T, Nakayama T, Hayashi K, Itoh H. DNA-damaged podocyte-CD8 T cell crosstalk exacerbates kidney injury by altering DNA methylation. Cell Rep 42: 112427, 2023 (* equally contributed)

41. Miyamoto K, Hayabuchi H, Tokifuji Y, Ando M, Onishi N, Okamura T, Yoshimura A, Chikuma S (Corresponding Author). A Protein Kinase D inhibitor suppresses AKT on T cells and antagonizes cancer immunotherapy by Anti-PD-1. Int Immunol 16, dxac035, 2022

40. Chikuma S (Corresponding Author)., Yamanaka S, Nakagawa S, Ueda MT, Hayabuchi H, Tokifuji Y, Kanayama M, Okamura T, Arase H, Yoshimura A.

TRIM28 Expression on Dendritic Cells Prevents Excwssive T cell Priming by silessing endogenous retrovirus. J Immunol 2021 Apr 1;206(7):1528-1539

39. Sakai R, Ito M, Yoshimoto K, Chikuma S, Kurasawa T, Kondo T, Suzuki K, Takeuchi T, Amano K, Yoshimura A.

Tocilizumab monotherapy uncovered the role of the CCL22/17-CCR4+ Treg axis during remission of crescentic glomerulonephritis.

Clin Transl Immunology. 9:e1203, 2020

38. Kondo T, Ando M, Nagai N, Tomisato W, Srirat T, Liu B, Mise-Omata S, Ikeda M, Chikuma S, Nishimasu H, Nureki O, Ohmura M, Hayakawa N, Hishiki T, Uchibori R, Ozawa K, Yoshimura A. The NOTCH-FOXM1 Axis Plays a Key Role in Mitochondrial Biogenesis in the Induction of Human Stem Cell Memory-like CAR-T Cells Cancer Research 80: 471-483, 2020

37,. Kondo T, Imura Y, Ando M, Chikuma S, Yoshimura A In Vitro Conversion of Activated T Cells into Stem Cell Memory-Like T Cells Methods Mol Biol 2048:41-51.

36 Goto M, .Chamoto K, Higuchi K, Yamashita S, Noda K, Iino T, Miura M, Yamasaki T, Ogawa S, Sonobe M, Date H, Hamanishi J, Mandai M, Tanaka Y, Chikuma S, Hatae R Muto M,, Minamiguchi S, Minato M, Honjo T. Analytical performance of a new automated chemiluminescent magnetic immunoassays for soluble PD-1, PD-L1, and CTLA-4 in human plasma. Scientific Reports 9: 10144, 2019

35. Tsuda M, Ogawa S, Ooka M, Kobayashi K, Hirota K, Wakasugi M, Matsunaga T, Sakuma T, Yamamoto T, Chikuma S, Sasanuma H, Debatisse M, Doherty AJ, Fuchs RP, Takeda S PDIP38/PolDIP2 controls the DNA damage tolerance pathways by increasing the relative usage of translesion DNA synthesis over template switching. PLos One 14: e0213383, 2019.

34. Nakatsukasa H, Oda M, Yin J, Chikuma S, Ito M, Koga-Iizuka M, Someya K, Kitagawa Y, Ohkura N, Sakaguchi S, Koya I, Sanosaka T, Kohyama J, Tsukada YI, Yamanaka S, Takamura-Enya T, Lu Q, Yoshimura A Loss of TET proteins in regulatory T cells promotes abnormal proliferation, FoxP3 destabilization, and IL-17 expression. Int Immunol. , 2019.

33. Ito M, Komai K, Mise-Omata S. Iizuka-Koga M, Noguchi Y, Kondo T, Sakai R, Matsuo K, Nakayama T, Yoshie, O, Nakatsukasa H, Chikuma S, Shichita, T, Yoshimura A Brain regulatory T cells suppress astrogliosis and potentiate neurological recovery. Nature 565: 246-250, 2019.

32. Kanamori M, Nakatsukasa H, Ito M, Chikuma S, Yoshimura A Reprogramming of Th1 cells into regulatory T cellls through rewiring of the metabolic status. Int Immunol 30: 357-373, 2018.

31. Kondo T, Imura Y, Chikuma S, Hibino S, Omata-Mise S, .Ando M, Akanuma, T, Iizuka M, Sakai R, Morita R, Yoshimura A Generartion and application of human induced-stem cell memory T cells for adoptive immunotherapy. Cancer Sci 109: 2130-2149, 2018

30. Hibino S, Chikuma S, Kondo T, Ito M, Nakatsukasa H, Omata-Mise S, Yoshimura A. Inhibition of Nr4a receptors enhances anti-tumor immunity by breaking Treg-mediated immune tolerance.  Cancer Research Mar 20[Epubahead of print], 2018.

29. Kasahara H, Kondo T, Nakatsukasa H, Chikuma S, Ito M, Amdo M, Kurebayashi Y, Sekiya T, Yamada T, Okamoto S, Yoshimura A.   Genaration of allo-antigen-specific induced Treg stabilized by vitamine C treatment and its application for acute graft versus host disease model. Int Immunol 29: 457-469, 2017.

28. Kondo T, Morita R, Okuzono Y, Nakatsukasa H, Sekiya T, Chikuma S, ShichitaT, Kanamori M, Kubo M, Koka K, Miyazaki T, Kassai Y, Yoshimura A.

Notch-mediated conversion of activated T cells into stem cell memory-like T cells foradoptive immunotherapy  Nature Communications 8: 15338, 2017.

27. Komai K, Shichita T, Ito M, Kanamori M, Chikuma S, Yoshimura A  Role of scavenger receptors as damage-associated molecular pattern receptos in TLR activation.  Int Immunol 29: 59-70, 2017.

26 Zhang B*, Chikuma S*, Hori S, Fagarasan S, Honjo T  Non-overlapping rolesof PD-1 and FoxP3 in maintaining immune tolerance in a novel autoimmune pancreatitis mouse model.  Proc. Nat. Acad .Sci.  USA 113 8490-5,2016 (*:equal contribution)

25 Sakaguchi R, Chikuma S, Shichita T, Morita R, Sekiya T, Ouyang W, Ueda T, SekiH, Morisaki H, Yoshimura A. Innate-like function of memory Th17 cells for enhancing endotoxin-induced acute lung inflammation through IL-22.Int Immunol 28, 233-43, 2015

24. Hamanishi J, Mandai M, Ikeda T, Minami M, Kawaguchi A, Murayama T, Kanai M, Mori Y, Matsumoto S, Chikuma S, Matsumura N, Abiko K, Baba T, Yamaguchi K,Ueda A, Hosoe Y, Morita S, Yokode M, Shimizu A, Honjo T, Konishi I　　Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer.　J. Clin. Oncol.. 33, 4015-22, 2015

23. Stumpf M, Zhou X, Chikuma S, Bluestone JA  Tyrosine 201 of thecytoplasmic tail of CTLA-4 critically affects T regulatory cell suppressive function. Eur J Immunol 44: 1737-46, 2014.

22. Nguyen T, Xu J, Chikuma S, Hiai H, Kinoshita K, Moriya K, Koike K, Marcuzzi GP, Pfister H, Honjo T, Kobayashi M  Activation-induced cytidine deaminase is dispensable for virus-mediated liver and skin tumor development in mouse models.  Int Immunol 26: 397-406, 2014.

21. Rui Y, Honjo T, Chikuma S　Programmed cell death 1 inhibits inflammatory helper T-cell development through controlling the innate immune response.  Proc. Nat. Acad .Sci.  USA 110:16073-8, 2013.

20. Hara-Chikuma M, Chikuma S, Sugiyama Y, Kabashima K, Verkman AS, InoueS, Miyachi Y.  Chemokine-dependent T cell migration requires aquaporin-3-mediated hydrogen peroxide uptake.  J Exp Med 301 245-52, 2012  

19.Chikuma S, Suita N, Okazaki IM, Shibayama S, Honjo T.　　TRIM28 prevents autoinflammatory T cell development in vivo.  Nat Immunol.  13：596-603, 2012

18. Qin H, Suzuki K, Nakata M, Chikuma S, Izumi N, Huong Le T, Maruya M, Fagarasan, S, Busslinger M, Honjo T, Nagaoka H.   Activation-induced cytidine deaminase expression in CD4+ T cells is associated with a unique IL-10-producing subset that increases with age.  Plos One ;6: e29141, 2011

17. Terawaki S*, Chikuma S*, Shibayama S*, Hayashi T, Yoshida T, Okazaki T, Honjo T.　　IFN-α directly promotes programmed cell death-1 transcription and limits the duration of T cell-mediated immunity.　J Immunol 186:　2772-9, 2011 (* equal contribution)

16. Wang J, Okazaki IM, Yoshida T, Chikuma S, Kato Y, Nakaki F, Hiai H, Honjo T, Okazaki T    PD-1 deficiency results in the development of fatal myocarditis in MRL mice.  Int Immunol  22: 443-52. 2010 

15. Chikuma S, Terawaki S, Hayashi T, Nabeshima R, Yoshida T, Shibayama S, Okazaki T, Honjo T.   PD-1-mediated suppression of IL-2 production induces CD8+ T cell anergy in vivo.  J Immunol 1: 182: 6682-9, 2009  

14. Jiang F, Yoshida T, Nakaki F, Terawaki S, Chikuma S, Kato Y, Okazaki IM, HonjoT, Okazaki T.    Identification of QTLs that modify peripheral neuropathy in NOD.H2b-Pdcd1-/- mice.  Int Immunol 21:499-509, 2009.

13. Hara-Chikuma M, Takahashi K, Chikuma S, Verkman AS, Miyachi Y.  The expression of differentiation markers in aquaporin-3 deficient epidermis.  Arch Dermatol Res 301: 245-52, 2009   

12. Chikuma S, Bluestone JA  Expression of CTLA-4 and FOXP3 in cis protects from lethal lymphoproliferative disease.  Eur J Immunol ;37: 1285-9, 2007

11. Chikuma S, Bluestone JA    B7 independent T cell inhibition by CTLA-4.  J Immunol 175: 177-81, 2005 

10. Ogasawara K, Hamerman J, Hsin H, Chikuma S, Bour-Jordan H, Chen T, Pertel T, Carnaud C, Bluestone JA, Lanier LL  Impairment of NK cell function by NKG2D modulation in NOD mice.　Immunity ;18: :41-51, 2003  

9. Chikuma S, Imboden J, Bluestone JA  Negative regulation of T cell receptor-lipid raft interaction by cytotoxic T lymphocyte-associated antigen 4.  J Exp Med 197: 129-35 2003 

8. Ijima K, Murakami M, Okamoto H, Inobe M, Chikuma S, Saito I, Kanegae Y, Kawaguchi Y, Kitabatake A, Uede T  Successful gene therapy via intraarticular injection of adenovirus vector containing CTLA4IgG in a murine model of type II collagen-induced arthritis.  Human Gene Therapy 12: 1063-77, 2001

7. Takehara M, Murakami M, Inobe M, Tanaka K, Chikuma S, Saito I, Kanegae Y, Yasunami Y, Nakano M, Yamashita K, Todo S, Uede T   Long-term acceptance of allografts by in vivo gene transfer of regulatable adenovirus vector containing CTLA4IgG and loxP.  Human Gene Therapy 12: 415-26, 2001  

6. Chikuma S, Murakami M, Tanaka K, Uede T.  Janus kinase 2 is associated with a box 1-like motif and phosphorylates a critical tyrosine residue in the cytoplasmic region of cytotoxic T lymphocyte associated molecule-4.  J Cell Biochem  78: 241-50, 2000  

5. Kon S, Maeda M, Segawa T, Hagiwara Y, Horikoshi Y, Chikuma S, Tanaka K, Rashid MM, Inobe M, Chambers AF, Uede T   Antibodies to different peptides in osteopontin reveal complexities in the various secreted forms.  J Cell Biochem 77: 487-98, 2000 

4. Takiguchi M, Murakami M, Nakagawa I, Rashid MM, Tosa N, Chikuma S, Hashimoto A, Uede T.  Involvement of CD28/CTLA4-B7 costimulatory pathway in the development of lymphadenopathy and splenomegaly in MRL/lpr mice.  J Vet Med Sci. 62: 29-36, 2000

3. Takiguchi M, Murakami M, Nakagawa I, Yamada A, Chikuma S, Kawaguchi Y, Hashimoto A, Uede T.  Blockade of CD28/CTLA4-B7 pathway prevented autoantibody-related diseases but not lung disease in MRL/lpr mice.  Laboratory Investigations 79: 317-26, 1999.

2. Katagiri YU, Sleeman J, Fujii H, Herrlich P, Hotta H, Tanaka K, Chikuma S, Yagita H, Okumura K, Murakami M, Saiki I, Chambers AF, Uede T.    CD44 variants but not CD44s cooperate with beta1-containing integrins to permit cellsto bind to osteopontin independently of arginine-glycine-aspartic acid, therebystimulating cell motility and chemotaxis.  Cancer Res. 1999 Jan 1;59(1):219-26

1. Nakagawa I, Murakami M, Ijima K, Chikuma S, Saito I, Kanegae Y, Okamoto H, Kitabatake A, Uede T.   Persistent and secondary adenovirus-mediated hepatic gene expression using adenovirus vector containing CTLA4IgG.  Human Gene Therapy. 9: 1739-45, 1998 

Reviews and Book Chaptor

(Sorted present to past)

Presentation

(selected, sorted present to past)